2197
COM:CLOVERBIOPHARMA
Clover Biopharmaceuticals
- Stock
Last Close
0.28
25/11 07:31
Market Cap
415.27M
Beta: -
Volume Today
313K
Avg: -
Preview
Full access to financials is available to subscribers only. Please support our work and get full access to all features. You can cancel anytime. If you'd like a demo, free trial or have any questions, please checkout the help page
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | ||
|---|---|---|---|---|---|---|
average inventory | 25.64M - | 409.79M 1,498.42% | 1.58B 284.72% | 1.54B 2.27% | ||
average payables | 20.49M - | 311.19M 1,418.55% | 722.76M 132.26% | 552.40M 23.57% | ||
average receivables | 5.09M - | |||||
book value per share | -0.06 - | -0.85 1,349.00% | 2.64 410.90% | -0.59 - | ||
capex per share | -0.01 - | -0.10 1,569.48% | -0.17 76.88% | |||
capex to depreciation | -2.84 - | -19.67 591.87% | -3.16 83.92% | -1.76 44.47% | ||
capex to operating cash flow | 0.26 - | -0.24 193.17% | 0.09 136.68% | 0.06 28.66% | ||
capex to revenue | ||||||
cash per share | 0.14 - | 0.70 408.22% | 6.20 790.61% | 0.60 - | ||
days of inventory on hand | 148.56 - | |||||
days payables outstanding | 52.82 - | |||||
days sales outstanding | 224.14 - | |||||
debt to assets | 0.07 - | 0.02 71.90% | 0.01 32.39% | 0.08 494.09% | 0.15 99.16% | |
debt to equity | -0.18 - | -0.02 87.63% | 0.06 345.34% | -0.53 1,052.02% | -0.43 18.72% | |
dividend yield | 0.02 - | |||||
earnings yield | -0.00 - | -0.07 1,549.91% | -1.19 1,535.12% | -0.21 - | ||
enterprise value | 13.27B - | 12.14B 8.53% | 2.38B 80.42% | -1.25B 152.71% | 244.83M 119.54% | |
enterprise value over ebitda | -370.16 - | -13.43 96.37% | -0.40 97.04% | 0.53 232.31% | -0.09 118.07% | |
ev to operating cash flow | -498.61 - | 25.45 105.10% | -2.59 110.18% | 0.74 128.61% | ||
ev to sales | 6.24 - | |||||
free cash flow per share | -0.03 - | 0.31 1,186.16% | -2.16 788.80% | |||
free cash flow yield | -0.00 - | 0.03 1,252.77% | -0.20 783.96% | |||
graham net net | -0.08 - | -1.16 1,306.57% | -1.90 64.04% | -1.38 - | ||
graham number | 0.26 - | 3.89 1,400.85% | 27.80 615.51% | 1.22 - | ||
income quality | 0.55 - | -0.52 195.36% | 0.15 129.20% | 0.69 352.06% | ||
intangibles to total assets | 0.00 - | 0.00 85.23% | 0.00 1,008.98% | 0.01 188.19% | 0.02 154.43% | |
interest coverage | -3.70 - | -306.06 8,167.08% | -2.39K 679.83% | -412.51 82.72% | ||
interest debt per share | 0.02 - | 0.02 10.98% | 0.15 598.05% | 0.25 - | ||
inventory turnover | 2.46 - | |||||
invested capital | -0.18 - | -0.02 87.63% | 0.06 345.34% | -0.53 1,052.02% | -0.43 18.72% | |
market cap | 13.41B - | 12.63B 5.78% | 5.08B 59.82% | 664.78M - | ||
net current asset value | -89.69M - | -1.12B 1,150.77% | 949.98M 184.68% | -972.91M 202.41% | -934.75M 3.92% | |
net debt to ebitda | 3.80 - | 0.55 85.62% | 0.45 17.49% | 0.53 16.51% | 0.16 69.01% | |
net income per share | -0.05 - | -0.79 1,454.56% | -13.02 1,546.69% | -0.11 - | ||
operating cash flow per share | -0.02 - | 0.41 1,891.81% | -1.99 582.25% | |||
payables turnover | 6.91 - | |||||
receivables turnover | 1.63 - | |||||
research and ddevelopement to revenue | 16.56 - | |||||
return on tangible assets | -0.32 - | -0.77 143.44% | -1.13 46.31% | -0.53 53.38% | -0.07 87.23% | |
revenue per share | 0.03 - | |||||
roe | 0.87 - | 0.93 7.29% | -4.94 629.66% | 3.67 174.34% | 0.19 94.85% | |
roic | 1.08 - | 0.97 9.98% | -4.44 556.28% | 9.65 317.34% | 6.26 35.14% | |
sales general and administrative to revenue | 5.06 - | |||||
shareholders equity per share | -0.06 - | -0.85 1,349.00% | 2.64 410.90% | -0.59 - | ||
stock based compensation to revenue | 1.36 - | |||||
tangible asset value | -68.12M - | -983.02M 1,343.15% | 1.21B 222.61% | -703.13M 158.34% | -772.69M 9.89% | |
tangible book value per share | -0.06 - | -0.85 1,343.15% | 2.61 407.28% | -0.62 - | ||
working capital | 136.86M - | 981.69M 617.30% | 2.93B 198.30% | 1.56B 46.70% | -377.48M 124.19% |
All numbers in HKD (except ratios and percentages)